ConductScience.org, home

Paper30065564

Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis.

Jiang XW and 3 others. World J Gastroenterol, 2018. Cited by 25 papers, by iCite.

Cite this record

ConductScience Library. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis. Papers, record 30065564. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30065564

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis.
PubMed
Journal
World J Gastroenterol
PubMed
Year
2018
PubMed
Publication types
Journal Article, Meta-Analysis, Systematic Review
PubMed
Citations, by iCite
25
iCite
Relative citation ratio, by iCite
1.08
iCite
Revised in PubMed
2025-06-23
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Jiang XWXian-Wan
2Ye JZJian-Zhong
3Li YTYa-Ting
4Li LJLan-Juan

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antiviral AgentsMajor topic
CoinfectionMajor topic
Hepatitis BMajor topic
Hepatitis B virusMajor topic
Hepatitis CMajor topic
Antibiotic Prophylaxis
Disease Progression
Guanine
Hepatitis B Surface Antigens
Humans
Incidence
Interferons
Recurrence
Tenofovir
Treatment Outcome
Virus Activation

Source PubMed

Download CSV of topics

References49

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119669238Dual chronic hepatitis B virus and hepatitis C virus infection.Hepatol Int2009https://conductscience.org/library/papers/19669238PubMed
228230928Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals.J Gastroenterol Hepatol2017https://conductscience.org/library/papers/28230928PubMed
319596477Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells.J Hepatol2009https://conductscience.org/library/papers/19596477PubMed
427667367EASL Recommendations on Treatment of Hepatitis C 2016.J Hepatol2017https://conductscience.org/library/papers/27667367PubMed
528552801Interferon-Free Regimens in Hepatitis B Surface Antigen/Anti-Hepatitis C Virus Positive Patients: The Need to Control Hepatitis B Virus Replication to Avoid Hepatitis B Virus Reactivation.Clin Gastroenterol Hepatol2017https://conductscience.org/library/papers/28552801PubMed
617302256Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy.Antivir Ther2006https://conductscience.org/library/papers/17302256PubMed
711693335High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial.Am J Gastroenterol2001https://conductscience.org/library/papers/11693335PubMed
827394647The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013.Lancet2016https://conductscience.org/library/papers/27394647PubMed
928195337Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis.Hepatology2017https://conductscience.org/library/papers/28195337PubMed
1019812441The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin.Antivir Ther2009https://conductscience.org/library/papers/19812441PubMed
1119084016Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.Gastroenterology2009https://conductscience.org/library/papers/19084016PubMed
1222102386Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus.Korean J Hepatol2011https://conductscience.org/library/papers/22102386PubMed
1327367295Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV.Antivir Ther2016https://conductscience.org/library/papers/27367295PubMed
1428206681Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen.Aliment Pharmacol Ther2017https://conductscience.org/library/papers/28206681PubMed
1518490796Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.Neth J Med2008https://conductscience.org/library/papers/18490796PubMed
1618490077The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection.J Hepatol2008https://conductscience.org/library/papers/18490077PubMed
1731816111
Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.
Hepatology2020https://conductscience.org/library/papers/31816111PubMed
1817376043Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients.J Gastroenterol Hepatol2007https://conductscience.org/library/papers/17376043PubMed
1928437794
Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.
Ann Intern Med2017https://conductscience.org/library/papers/28437794PubMed
209282824Response of patients with dual hepatitis B virus and C virus infection to interferon therapy.J Interferon Cytokine Res1997https://conductscience.org/library/papers/9282824PubMed

See all 49 referencesDownload CSV of references

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.

PMIDTitleJournalYearIn PapersSource
40445953Risk of HBV reactivation in HBV/HCV-co-infected HCV-treated patients: A single-center study.PLoS One2025https://conductscience.org/library/papers/40445953PubMed
38881210
Hepatitis B transmission/reactivation associated with Hepatitis B core antibody and Hepatitis C nucleic acid testing positive organs: A report from the Organ Procurement and Transplantation Network Disease Transmission Advisory Committee.
Transpl Infect Dis2024https://conductscience.org/library/papers/38881210PubMed
37056462Synthesis and biological evaluation of esculetin derivatives as potential anti-HBV agents.Med Chem Res2023https://conductscience.org/library/papers/37056462PubMed
37022602Low Rate of Hepatitis B Reactivation Among Patients with Chronic Hepatitis C During Direct Acting Antiviral Therapy.Dig Dis Sci2023https://conductscience.org/library/papers/37022602PubMed
36815093Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance.J Hepatocell Carcinoma2023https://conductscience.org/library/papers/36815093PubMed
36556178Direct-Acting Antivirals and the Risk of Hepatitis B Reactivation in Hepatitis B and C Co-Infected Patients: A Systematic Review and Meta-Analysis.J Pers Med2022https://conductscience.org/library/papers/36556178PubMed
36158908Challenge of managing hepatitis B virus and hepatitis C virus infections in resource-limited settings.World J Hepatol2022https://conductscience.org/library/papers/36158908PubMed
35663152The dilemma of cytomegalovirus and hepatitis B virus interaction.Gastroenterol Rep (Oxf)2022https://conductscience.org/library/papers/35663152PubMed
34378349Profiling the physiological pitfalls of anti-hepatitis C direct-acting agents in budding yeast.Microb Biotechnol2021https://conductscience.org/library/papers/34378349PubMed
32108916Direct-acting antiviral treatment downregulates immune checkpoint inhibitor expression in patients with chronic hepatitis C.Clin Exp Med2020https://conductscience.org/library/papers/32108916PubMed
32102898Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy.Clin Microbiol Rev2020https://conductscience.org/library/papers/32102898PubMed
31969598Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway.Sci Rep2020https://conductscience.org/library/papers/31969598PubMed
31413526Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions.World J Gastroenterol2019https://conductscience.org/library/papers/31413526PubMed
30687740Recent Advances in HBV Reactivation Research.Biomed Res Int2018https://conductscience.org/library/papers/30687740PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30065564

GET https://conductscience.org/api/papers/v1/30065564/references?page=2